Endocrine Abstracts

There is increasing recognition that Thyroid Cancer represents a group of diseases with a broad spectrum of malignant behavior, ranging from the indolent papillary microcarcinoma carrying essentially no risk to the patients’ health of life; to Anaplastic Thyroid Cancer, the most aggressive human malignancy. The majority of our patients lie between these two extremes and their clinical management must increasingly be predicated on the threat that the disease represents to ...

Radioiodine is a central treatment modality for differentiated thyroid cancer. Whilst its utility for post-surgery ablation in some patients remains controversial, the importance of radioiodine in the treatment of recurrent and metastatic disease is clear. Advanced disease which no longer takes up radioiodine (radioiodine-refractory DTC (RR-DTC)) is commonly associated with a poor prognosis, with 10-year survival rates for metastatic RR-DTC <10%. Although new systemic ther...

Thyroid cancer remains the most common endocrine malignancy worldwide and its incidence and mortality has increased steadily over the last four decades. In general terms it has a good outcome, however, some patients develop aggressive forms of thyroid cancer that are untreatable and the molecular bases are poorly understood. These aggressive forms have lost NIS (Na/I Symporter) function, one of the most important hallmarks during thyroid cancer progression as it leads to radio...